EP Patent

EP3466431A1 — Crystalline forms and methods for preparing sglt2 inhibitors

Assigned to MSD International Holdings GmbH · Expires 2019-04-10 · 7y expired

What this patent protects

This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and ( S )-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.

USPTO Abstract

This invention relates to methods for preparing a sodium-glucose transporter 2 (SGLT2) inhibitor, a cocrytalline SGLT2 and ( S )-5-oxopyrrolidine-2-carboxylic acid (L-PGA) complex, and intermediates useful in the preparation of the said SGLT2 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP3466431A1
Jurisdiction
EP
Classification
—
Expires
2019-04-10
Drug substance claim
No
Drug product claim
No
Assignee
MSD International Holdings GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.